scholarly journals Clinical Implication of p53 Overexpression in Breast Cancer Patients Younger than 50 Years with a Triple-negative Subtype Who Undergo a Modified Radical Mastectomy

2011 ◽  
Vol 41 (7) ◽  
pp. 854-866 ◽  
Author(s):  
D.-S. Lee ◽  
S. H. Kim ◽  
Y. J. Suh ◽  
S. Kim ◽  
H. K. Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Implication ◽  
Triple Negative ◽  
Radical Mastectomy ◽  
Breast Cancer Patients ◽  
Modified Radical Mastectomy ◽  
P53 Overexpression ◽  
Triple Negative Subtype

scholarly journals A Randomized Prospective Trial of Radical (Halsted) Mastectomy Versus Modified Radical Mastectomy in 311 Breast Cancer Patients

1983 ◽  
Vol 198 (2) ◽  
pp. 207-212 ◽  
Author(s):  
WILLIAM A. MADDOX ◽  
JOHN T. CARPENTER ◽  
HENRY L. LAWS ◽  
S. J. SOONG ◽  
GRETCHEN CLOUD ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prospective Trial ◽  
Radical Mastectomy ◽  
Breast Cancer Patients ◽  
Modified Radical Mastectomy ◽  
Randomized Prospective Trial

scholarly journals High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Huikun Zhang ◽  
Yawen Zhao ◽  
Xiaoli Liu ◽  
Li Fu ◽  
Feng Gu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
High Expression ◽  
Breast Cancer Patients ◽  
The Relationship ◽  
Triple Negative Subtype

BackgroundBreast cancer is the most commonly diagnosed cancer worldwide. However, the well-known biomarkers are not enough to meet the needs of precision medicine. Novel targets are desirable and highly valuable for improved patient survival. In this regard, we identified complement component C7 as one of the candidates based on data from the OCOMINE database.MethodsC7 expression was examined by immunohistochemistry in 331 cases of invasive ductal carcinoma (IDC), 45 cases of ductal carcinoma in situ (DCIS), and 52 cases of non-neoplastic tissues adjacent to tumor. Then, C7 expression was further confirmed by Western blot analysis based on IDC specimens and non-neoplastic breast specimens. The relationship between the C7 expression and prognosis of breast cancer patients was analyzed in order to investigate the function of C7 in breast cancer patients. Meanwhile, we also analyzed the relationship between the C7 expression and prognosis of 149 patients treated with conventional TE (taxane and anthracycline)-based chemotherapy. Then, a cohort of patients (22 cases) treated with TE neoadjuvant chemotherapy was used to further confirm the relationship between the C7 expression and TE-based chemosensitivity.ResultsIn our present study, we reported for the first time that C7 was an independent prognostic factor of breast cancer and C7 expression of IDC tissues was higher than non-neoplastic tissues adjacent to tumor and DCIS. In a cohort of 331 IDC patients, high expression of C7 indicated poor prognosis especially in the triple negative subtype and luminal B subtype. Furthermore, C7 was also a promoting factor for triple negative subtype patients to develop bone metastasis. Meanwhile, we provided the first evidence that patients with high C7 expression were insensitive to TE (taxane and anthracycline)-based chemotherapy by analyzing a cohort of 149 patients treated with TE-based chemotherapy and another cohort of 22 patients treated with TE neoadjuvant chemotherapy.ConclusionsIn summary, high expression of C7 may promote breast cancer development and might be insensitive to TE-based chemotherapy. Our present study laid a foundation to help clinicians improve the identification of patients for TE-based chemotherapy by C7 in the era of precision medicine.

Frequency of TLE3 overexpression in breast carcinoma subtypes including a large cohort of triple-negative patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1040-1040
Author(s):  
Gargi D. Basu ◽  
Anatole Ghazalpour ◽  
David Arguello ◽  
Raheela Ashfaq ◽  
Zoran Gatalica ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Large Cohort ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Hormone Receptor Positive ◽  
Triple Negative Subtype

1040 Background: The taxanes are an important class of agents for the treatment of a broad range of malignancies including breast cancer. They improve survival in patients with early stage and metastatic breast cancer. Transducin-like enhancer of split 3 (TLE3) is a transcriptional repressor which influences growth and microtubule stability and its expression has been implicated in response to taxane therapy in breast cancer. We investigated the tumor expression of TLE3 in breast cancer patients, including a large cohort of the triple negative subtype. Methods: We analyzed TLE3 (M-201), ER(1D5), PR(PgR636) and HER2/neu(Polyclonal) expression by immunohistochemistry in 978 breast cancer patients. Immunoreactivity was assessed by scoring the percentage of cells stained in each field and by the intensity of staining. Results: To sub-classify the 978 breast cancer patients, we utilized hormone receptors (ER and PR) and HER2 expression/amplification. Overall, 36% of the total breast cancer patients were hormone receptor positive, 15% were HER2 positive and 49% were triple negative. The percentage of triple negative patients was higher in our cohort, given the fact that molecular profiling services are used more frequently for this subtype. A total of 477 patients were triple negative of which 61% stained positive for TLE3 expression. Of the 150 HER2 positive patients, 73% stained positive for TLE3 expression as compared with 82% TLE3 positivity in the 351 hormone receptor positive patients. By pairwise comparison, the hormone receptor positive vs triple-negative subtype showed the highest statistical significance in ratios of TLE3 positives (p =2.5e-10). Conclusions: Our results show that TLE3 is over-expressed in the majority of HER2 positive and hormone receptor positive breast cancer patients. Interestingly, the frequency of over-expression of TLE3 was lowest in the triple negative subtype thereby making it more important to identify those patients in this group who are most likely to respond to taxanes prior to therapy. To our knowledge, this is the first study providing a comprehensive review of TLE expression in breast cancer subtypes.

Sign in / Sign up

Export Citation Format

Share Document